AM251 drug
Evidence from:
primary |
all sources
Related entities (5)
| Subject | Relation | Object | p-value | Evidence |
|---|---|---|---|---|
| AM251 | interacts_with | CB1 receptor | 0.08 | 1 |
| AM251 | targets | CB1 receptor | — | 1 |
| AM251 | regulates | fEPSP | 0 | 1 |
| AM251 | regulates | long-term potentiation | 0 | 1 |
| AM251 | regulates | LTP | 0 | 1 |
Mentioned in (8)
Papers in which this entity is mentioned.
- Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. (2014)
- Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? (2014)
- Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential. (2014)
- Adolescent chronic mild stress alters hippocampal CB1 receptor-mediated excitatory neurotransmission and plasticity. (2013)
- Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. (2012)
- The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. (2012)
- Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. (2012)
- Repeated homotypic stress elevates 2-arachidonoylglycerol levels and enhances short-term endocannabinoid signaling at inhibitory synapses in basolateral amygdala. (2009)
Merged raw entities (2)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| am251 | drug | 8 | 18 |
| n-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide | drug | — | — |